New combo approach aims to keep prostate cancer sensitive to hormone therapy longer
NCT ID NCT06734130
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 36 times
Summary
This study tests a new way of giving hormone therapy (androgen deprivation) along with chemotherapy (docetaxel) for men with stage IV prostate cancer that still responds to hormones. The goal is to see if this approach can keep the cancer sensitive to hormone treatment for at least 3 years. About 25 men will take part, and the study is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Caner Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.